GEAP201914608A - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents

Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Info

Publication number
GEAP201914608A
GEAP201914608A GEAP201914608A GEAP2019014608A GEAP201914608A GE AP201914608 A GEAP201914608 A GE AP201914608A GE AP201914608 A GEAP201914608 A GE AP201914608A GE AP2019014608 A GEAP2019014608 A GE AP2019014608A GE AP201914608 A GEAP201914608 A GE AP201914608A
Authority
GE
Georgia
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
GEAP201914608A
Other languages
English (en)
Georgian (ka)
Inventor
Natasha Kinsella
Susanne Wright
Hannah Canning
Devid Harrison
Kerry Jenkins
David Livermore
Saleh Ahmed
Gregory Barker
Richard Davenport
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of GEAP201914608A publication Critical patent/GEAP201914608A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
GEAP201914608A 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors GEAP201914608A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
GEAP201914608A true GEAP201914608A (en) 2019-10-10

Family

ID=53051992

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201914608A GEAP201914608A (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
GEAP201614608A GEP20207095B (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201614608A GEP20207095B (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (2) GEAP201914608A (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119835C2 (uk) 2016-02-24 2019-08-12 Пфайзер Інк. ПОХІДНІ ПІРАЗОЛО[1,5-а]ПІРАЗИН-4-ІЛУ ЯК JAK-ІНГІБІТОРИ
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN115413277B (zh) * 2020-04-20 2023-08-01 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
WO2022083569A1 (en) * 2020-10-20 2022-04-28 Amgen Inc. Heterocyclic spiro compounds and methods of use
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
AR127488A1 (es) 2021-10-28 2024-01-31 Insilico Medicine Ip Ltd Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
EP4447963A1 (en) * 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
WO2023129958A2 (en) 2021-12-28 2023-07-06 ATAI Life Sciences AG Nitric oxide releasing prodrugs of mda and mdma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
PL360027A1 (en) 2000-06-30 2004-09-06 Wyeth Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
CL2017002354A1 (es) 2018-05-04
DK3271357T3 (da) 2020-02-17
WO2016148306A1 (en) 2016-09-22
KR102609431B1 (ko) 2023-12-04
GEP20207095B (en) 2020-04-10
US20180072714A1 (en) 2018-03-15
EP3271357B1 (en) 2019-11-27
US10287286B2 (en) 2019-05-14
BR112017019653B1 (pt) 2023-10-03
JP2018512408A (ja) 2018-05-17
SG11201707280VA (en) 2017-10-30
EP3271357A1 (en) 2018-01-24
KR20170129874A (ko) 2017-11-27
ES2774052T3 (es) 2020-07-16
AU2016234209B2 (en) 2020-08-27
CR20170468A (es) 2018-04-27
CA2979024C (en) 2024-02-20
MX2017011902A (es) 2017-12-15
DOP2017000209A (es) 2017-10-15
EA035739B1 (ru) 2020-08-03
MY194873A (en) 2022-12-21
ECSP17069696A (es) 2018-02-28
IL254277A0 (en) 2017-10-31
NZ735631A (en) 2023-07-28
PH12017501699B1 (en) 2023-06-30
CN107531698B (zh) 2024-08-13
PT3271357T (pt) 2020-02-21
HK1249512A1 (en) 2018-11-02
BR112017019653A2 (pt) 2018-05-15
HUE047918T2 (hu) 2020-05-28
PH12017501699A1 (en) 2018-03-12
CN107531698A (zh) 2018-01-02
AU2016234209A1 (en) 2017-10-12
IL254277B (en) 2020-10-29
ZA201706612B (en) 2019-01-30
TN2017000384A1 (en) 2019-01-16
UA123668C2 (uk) 2021-05-12
CA2979024A1 (en) 2016-09-22
JP6726681B2 (ja) 2020-07-22
GB201504565D0 (en) 2015-05-06
EA201792057A1 (ru) 2018-04-30
PE20180656A1 (es) 2018-04-17
CO2017009353A2 (es) 2017-11-30

Similar Documents

Publication Publication Date Title
GEAP201914608A (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
GEAP202215535A (en) Compounds
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
SA520420033B1 (ar) مركبات صيدلية
CR20220251A (es) Nuevos derivados de metilquinazolinona
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EA202191286A1 (ru) Ингибитор 15-pgdh
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX394082B (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
GEAP202115281A (en) Spirocycle compounds and methods of making and using same
GEAP201814349A (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
MY194116A (en) Pharmaceutical compounds
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
GEAP202215588A (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
EA201692298A1 (ru) Производные карбоксамидов
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
PH12019502170A1 (en) Combination of isoindolinone derivatives with sgi-110
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine